fig4

Sequential treatment with doxorubicin and zoledronic acid has no additive effects in an aggressive model of established bone metastases

Figure 4. Osteolytic lesions, trabecular bone volume and the number of osteoclasts at the bone-tumor interface. Osteolytic lesion area was analyzed from X-ray images of both hind limbs, trabecular bone area and the number of osteoclasts in the bone-tumor interface in midsagittal histological sections of the left hind limb. A: Representative images showing established osteolytic lesions before treatment and at sacrifice; B: osteolytic lesion area was decreased in the ZOL and DOX + ZOL groups as measured by radiography; C: trabecular bone area was increased in the group receiving only ZOL, but the effect was not statistically significant in the DOX + ZOL group. Data are expressed as mean ± SD, n = 8 animals. Scale bars 2 mm, arrows osteolytic lesions. **Significantly different from control group (P < 0.01); ***significantly different from control group (P < 0.001); NS: non-significant; DOX: doxorubicin; ZOL: zoledronic acid

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/